{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:01:25Z","timestamp":1794340885792,"version":"4.9.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R25 GM090084"],"award-info":[{"award-number":["R25 GM090084"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R25 GM090084"],"award-info":[{"award-number":["R25 GM090084"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R25 GM089614"],"award-info":[{"award-number":["R25 GM089614"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["NIDA T32DA007027"],"award-info":[{"award-number":["NIDA T32DA007027"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["NIDA T32DA007027"],"award-info":[{"award-number":["NIDA T32DA007027"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32 MH020030"],"award-info":[{"award-number":["T32 MH020030"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32 MH020030"],"award-info":[{"award-number":["T32 MH020030"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH084894"],"award-info":[{"award-number":["R01 MH084894"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["P50AA022537"],"award-info":[{"award-number":["P50AA022537"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","award":["VCU Breakthroughs Fund"],"award-info":[{"award-number":["VCU Breakthroughs Fund"]}],"id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","award":["VCU Breakthroughs Fund"],"award-info":[{"award-number":["VCU Breakthroughs Fund"]}],"id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The psychoactive entactogen 3,4-methylenedioxymethamphetamine (MDMA), widely known as a recreational drug, is gaining renewed attention as a potential psychotherapeutic adjunct for treatment-resistant psychiatric disorders, yet its neurobiological mechanisms \u2013 particularly those related to its stereoisomers and sex-specific effects \u2013 remain poorly understood. Here, we report stereoselective and sex-dependent actions of MDMA on serotonin (or 5-hydroxytryptamine) 2A receptor (5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R)-mediated signaling and dendritic structural plasticity in mouse frontal cortex. Using both in vitro and in vivo approaches, we found that racemic MDMA and\n                    <jats:italic>S<\/jats:italic>\n                    (+)-MDMA exhibit weak partial agonism at 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R in HEK293 cells, whereas\n                    <jats:italic>R<\/jats:italic>\n                    (\u2013)-MDMA shows negligible functional activity despite higher specific binding affinity. In vivo,\n                    <jats:italic>S<\/jats:italic>\n                    (+)-MDMA elicited a dose-dependent head-twitch response (HTR) in both sexes, while\n                    <jats:italic>R<\/jats:italic>\n                    (\u2013)-MDMA-induced HTR only in females. Correspondingly,\n                    <jats:italic>S<\/jats:italic>\n                    (+)-MDMA increased inositol monophosphate (IP\n                    <jats:sub>1<\/jats:sub>\n                    ) accumulation in the frontal cortex of male and female mice, whereas\n                    <jats:italic>R<\/jats:italic>\n                    (\u2013)-MDMA showed minimal effects. Structurally,\n                    <jats:italic>S<\/jats:italic>\n                    (+)-MDMA enhanced dendritic spine density in male frontal cortex in a partially 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R-dependent manner, while no spine remodeling was observed in females or with\n                    <jats:italic>R<\/jats:italic>\n                    (\u2013)-MDMA. Pharmacological blockade of the serotonin transporter (SERT) with fluoxetine fully prevented\n                    <jats:italic>S<\/jats:italic>\n                    (+)-MDMA-induced HTR and IP\n                    <jats:sub>1<\/jats:sub>\n                    signaling, without affecting responses to the direct 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R agonist DOI. These findings indicate that MDMA engages 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R signaling indirectly via serotonin efflux and that this effect is both stereoselective and sex-dependent in mice, uncovering a previously unrecognized interaction between sex, MDMA stereochemistry, and 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    R-mediated cortical plasticity, with important implications for the rational design of MDMA-based therapeutics.\n                  <\/jats:p>","DOI":"10.1038\/s41386-025-02313-x","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:09:25Z","timestamp":1770041365000},"page":"1011-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice"],"prefix":"10.1038","volume":"51","author":[{"given":"Maya C.","family":"Gaines-Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Younkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karah N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Maltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de la Fuente Revenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-9312","authenticated-orcid":false,"given":"Jennifer T.","family":"Wolstenholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Glennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Dukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3105-3204","authenticated-orcid":false,"given":"Javier","family":"Gonz\u00e1lez-Maeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2313_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1749-6632.1990.tb16915.x","volume":"600","author":"M Teitler","year":"1990","unstructured":"Teitler M, Leonhardt S, Appel NM, De Souza EB, Glennon RA. Receptor pharmacology of MDMA and related hallucinogens. Ann N Y Acad Sci. 1990;600:626\u201338. discussion 638-29.","journal-title":"Ann N Y Acad Sci"},{"key":"2313_CR2","first-page":"917","volume":"165","author":"H Kalant","year":"2001","unstructured":"Kalant H. The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs. CMAJ. 2001;165:917\u201328.","journal-title":"CMAJ"},{"key":"2313_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O\u2019Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d). Pharmacol Rev. 2003;55:463\u2013508.","journal-title":"Pharmacol Rev"},{"key":"2313_CR4","unstructured":"Anderson GM, 3rd, Braun G, Braun U, Nichols DE, Shulgin AT. Absolute configuration and psychotomimetic activity. NIDA Res Monogr. 1978;22:8\u201315."},{"key":"2313_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1749-6632.1990.tb16913.x","volume":"600","author":"JW Gibb","year":"1990","unstructured":"Gibb JW, Johnson M, Stone D, Hanson GR. MDMA: historical perspectives. Ann N Y Acad Sci. 1990;600:601\u201311.","journal-title":"Ann N Y Acad Sci"},{"key":"2313_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cell.2016.06.045","volume":"166","author":"BD Heifets","year":"2016","unstructured":"Heifets BD, Malenka RC. MDMA as a probe and treatment for social behaviors. Cell. 2016;166:269\u201372.","journal-title":"Cell"},{"key":"2313_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med"},{"key":"2313_CR8","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"Mitchell","year":"2023","unstructured":"Mitchell, Ot\u2019alora GM JM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. Group MSC MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","journal-title":"Nat Med"},{"key":"2313_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","volume":"36","author":"JL Maples-Keller","year":"2022","unstructured":"Maples-Keller JL, Norrholm SD, Burton M, Reiff C, Coghlan C, Jovanovic T, et al. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol. 2022;36:368\u201377.","journal-title":"J Psychopharmacol"},{"key":"2313_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE. Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry. 2022;13:863088.","journal-title":"Front Psychiatry"},{"key":"2313_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/02698811241265352","volume":"38","author":"K Stocker","year":"2024","unstructured":"Stocker K, Liechti ME. Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: it is time to reconcile \u201cthe great entactogen-empathogen debate\u201d. J Psychopharmacol. 2024;38:685\u20139.","journal-title":"J Psychopharmacol"},{"key":"2313_CR12","doi-asserted-by":"crossref","unstructured":"Ceramella J, Iacopetta D, Franchini A, De Luca M, Saturnino C, Andreu I, et al. A look at the importance of chirality in drug activity: some significative examples. Appl Sci. 2022;12:10909.","DOI":"10.3390\/app122110909"},{"key":"2313_CR13","first-page":"70","volume":"5","author":"J McConathy","year":"2003","unstructured":"McConathy J, Owens MJ. Stereochemistry in drug action. Prim Care Companion J Clin Psychiatry. 2003;5:70\u20133.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2313_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","volume":"2","author":"LA Nguyen","year":"2006","unstructured":"Nguyen LA, He H. Pham-Huy C Chiral drugs: an overview. Int J Biomed Sci. 2006;2:85\u2013100.","journal-title":"Int J Biomed Sci"},{"key":"2313_CR15","doi-asserted-by":"crossref","unstructured":"Hanks JB, Gonz\u00e1lez-Maeso J. Molecular and cellular basis of hallucinogenic drug action. In: Preedy VR, editor. The Neuropathology of drug addiction and substance misuse. Elsevier; 2016.","DOI":"10.1016\/B978-0-12-800212-4.00075-3"},{"key":"2313_CR16","doi-asserted-by":"crossref","unstructured":"Hanks JB, Gonz\u00e1lez-Maeso J. Hallucinogens: circuits, behavior and translational models. In: Preedy VR, editor. The Neuropathology of drug addiction and substance misuse. London, UK: Elsevier; 2016.","DOI":"10.1016\/B978-0-12-800212-4.00076-5"},{"key":"2313_CR17","doi-asserted-by":"crossref","unstructured":"Marquardt GM, DiStephano V, Ling LL. Pharmacological effects of (\u00b1)-, (S)-, and (R+)-MDA. In: Stillman RC, Willette RE, editors. The psychopharmacology of hallucinogens. New York: Pergamon Press; 1978. pp. 84\u2013104.","DOI":"10.1016\/B978-0-08-021938-7.50011-4"},{"key":"2313_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0091-3057(84)90295-8","volume":"20","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Young R. Further investigation of the discriminative stimulus properties of MDA. Pharmacol Biochem Behav. 1984;20:501\u20135.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327\u201337.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2313_CR20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1111\/bph.13128","volume":"172","author":"A Rickli","year":"2015","unstructured":"Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol. 2015;172:3412\u201325.","journal-title":"Br J Pharmacol"},{"key":"2313_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/toxsci\/kfu222","volume":"143","author":"LE Lizarraga","year":"2015","unstructured":"Lizarraga LE, Cholanians AB, Phan AV, Herndon JM, Lau SS, Monks TJ. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(+\/-)-methylenedioxymethamphetamine. Toxicol Sci. 2015;143:209\u201319.","journal-title":"Toxicol Sci"},{"key":"2313_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1471-4159.2009.06474.x","volume":"112","author":"HH Sitte","year":"2010","unstructured":"Sitte HH, Freissmuth M. The reverse operation of Na(+)\/Cl(-)-coupled neurotransmitter transporters\u2013why amphetamines take two to tango. J Neurochem. 2010;112:340\u201355.","journal-title":"J Neurochem"},{"key":"2313_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bcp.2007.08.003","volume":"75","author":"LL Howell","year":"2008","unstructured":"Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol. 2008;75:196\u2013217.","journal-title":"Biochem Pharmacol"},{"key":"2313_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305\u201313.","journal-title":"J Psychoactive Drugs"},{"key":"2313_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0304-3940(94)90057-4","volume":"177","author":"JF Nash","year":"1994","unstructured":"Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett. 1994;177:111\u20135.","journal-title":"Neurosci Lett"},{"key":"2313_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00213-017-4812-5","volume":"235","author":"EG Pitts","year":"2018","unstructured":"Pitts EG, Curry DW, Hampshire KN, Young MB, Howell LL. (\u00b1)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. Psychopharmacology. 2018;235:377\u201392.","journal-title":"Psychopharmacology"},{"key":"2313_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","volume":"150","author":"JD McCorvy","year":"2015","unstructured":"McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther. 2015;150:129\u201342.","journal-title":"Pharmacol Ther"},{"key":"2313_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF Lopez-Gimenez","year":"2018","unstructured":"Lopez-Gimenez JF, Gonzalez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45\u201373.","journal-title":"Curr Top Behav Neurosci"},{"key":"2313_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1124\/jpet.109.156174","volume":"331","author":"KS Murnane","year":"2009","unstructured":"Murnane KS, Murai N, Howell LL, Fantegrossi WE. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. J Pharmacol Exp Ther. 2009;331:717\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"2313_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00213-002-1261-5","volume":"166","author":"WE Fantegrossi","year":"2003","unstructured":"Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, et al. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology. 2003;166:202\u201311.","journal-title":"Psychopharmacology"},{"key":"2313_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-004-2030-4","volume":"178","author":"DV Herin","year":"2005","unstructured":"Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology. 2005;178:505\u201313.","journal-title":"Psychopharmacology"},{"key":"2313_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.pbb.2005.10.008","volume":"82","author":"T Bondareva","year":"2005","unstructured":"Bondareva T, Wesolowska A, Dukat M, Lee M, Young R, Glennon RA. S(+)- and R(-)N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) as discriminative stimuli: effect of cocaine. Pharmacol Biochem Behav. 2005;82:531\u20138.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/0091-3057(92)90488-2","volume":"43","author":"RA Glennon","year":"1992","unstructured":"Glennon RA, Higgs R, Young R, Issa H. Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists. Pharmacol Biochem Behav. 1992;43:1099\u2013106.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pbb.2007.09.002","volume":"88","author":"R Young","year":"2008","unstructured":"Young R, Glennon RA. MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol Biochem Behav. 2008;88:318\u201331.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/02791072.1986.10472361","volume":"18","author":"AT Shulgin","year":"1986","unstructured":"Shulgin AT. The background and chemistry of Mdma. J Psychoactive Drugs. 1986;18:291\u2013304.","journal-title":"J Psychoactive Drugs"},{"key":"2313_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41386-024-01972-6","volume":"50","author":"I Straumann","year":"2024","unstructured":"Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, et al. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology. 2024;50:362\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"2313_CR37","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/s41380-023-02274-x","volume":"28","author":"AM Jaster","year":"2023","unstructured":"Jaster AM, Gonzalez-Maeso J. Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Mol Psychiatry. 2023;28:3595\u2013612.","journal-title":"Mol Psychiatry"},{"key":"2313_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68\u201372.","journal-title":"Science"},{"key":"2313_CR39","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25:1407\u201319.","journal-title":"Nat Neurosci"},{"key":"2313_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109836","volume":"37","author":"M de la Fuente Revenga","year":"2021","unstructured":"de la Fuente Revenga M, Zhu B, Guevara GA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.","journal-title":"Cell Rep"},{"key":"2313_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science"},{"key":"2313_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91\u20135.","journal-title":"Nature"},{"key":"2313_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439\u201352.","journal-title":"Neuron"},{"key":"2313_CR44","unstructured":"de la Fuente, Revenga M, Gonzalez-Maeso J. Snapshot IP (1) detection following 5-HT (2A) receptor stimulation in the mouse brain. ACS Chem Neuroscience. 2026. Online ahead of print."},{"key":"2313_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/acschemneuro.0c00291","volume":"12","author":"M de la Fuente Revenga","year":"2021","unstructured":"de la Fuente Revenga M, Shah UH, Nassehi N, Jaster AM, Hemanth P, Sierra S, et al. Psychedelic-like properties of quipazine and its structural analogues in mice. ACS Chem Neurosci. 2021;12:831\u201344.","journal-title":"ACS Chem Neurosci"},{"key":"2313_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49913-4","volume":"9","author":"M de la Fuente Revenga","year":"2019","unstructured":"de la Fuente Revenga M, Shin JM, Vohra HZ, Hideshima KS, Schneck M, Poklis JL, et al. Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo. Sci Rep. 2019;9:14247.","journal-title":"Sci Rep"},{"key":"2313_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2020.108595","volume":"334","author":"M de la Fuente Revenga","year":"2020","unstructured":"de la Fuente Revenga M, Vohra HZ, Gonzalez-Maeso J. Automated quantification of head-twitch response in mice via ear tag reporter coupled with biphasic detection. J Neurosci Methods. 2020;334:108595.","journal-title":"J Neurosci Methods"},{"key":"2313_CR48","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00213-022-06086-9","volume":"239","author":"MM Pantoni","year":"2022","unstructured":"Pantoni MM, Kim JL, Van Alstyne KR, Anagnostaras SG. MDMA and memory, addiction, and depression: dose-effect analysis. Psychopharmacology. 2022;239:935\u201349.","journal-title":"Psychopharmacology"},{"key":"2313_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/dmd.113.053678","volume":"42","author":"M Concheiro","year":"2014","unstructured":"Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA. Nonlinear pharmacokinetics of (+\/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos. 2014;42:119\u201325.","journal-title":"Drug Metab Dispos"},{"key":"2313_CR50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/nn.3181","volume":"15","author":"M Kurita","year":"2012","unstructured":"Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245\u201354.","journal-title":"Nat Neurosci"},{"key":"2313_CR51","doi-asserted-by":"publisher","first-page":"44301","DOI":"10.1074\/jbc.M112.413161","volume":"287","author":"JL Moreno","year":"2012","unstructured":"Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuellar F, et al. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A.mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem. 2012;287:44301\u201319.","journal-title":"J Biol Chem"},{"key":"2313_CR52","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1124\/mol.112.084582","volume":"83","author":"M Kurita","year":"2013","unstructured":"Kurita M, Moreno JL, Holloway T, Kozlenkov A, Mocci G, Garcia-Bea A, et al. Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol Pharmacol. 2013;83:1166\u201375.","journal-title":"Mol Pharmacol"},{"key":"2313_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102481","volume":"298","author":"JM Saunders","year":"2022","unstructured":"Saunders JM, Muguruza C, Sierra S, Moreno JL, Callado LF, Meana JJ, et al. Glucocorticoid receptor dysregulation underlies 5-HT(2A)R-dependent synaptic and behavioral deficits in a mouse neurodevelopmental disorder model. J Biol Chem. 2022;298:102481.","journal-title":"J Biol Chem"},{"key":"2313_CR54","unstructured":"Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. Comparative cytoarchitectonic atlas of the C57BL\/6 and 129\/Sv mouse brains. Amsterdam: Elsevier; 2002."},{"key":"2313_CR55","doi-asserted-by":"crossref","unstructured":"Neve RL. Overview of gene delivery into cells using HSV-1-based vectors. Curr Protoc Neurosci. 2012:Chapter 4:Unit 4.12.","DOI":"10.1002\/0471142301.ns0412s61"},{"key":"2313_CR56","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099\u2013108.","journal-title":"Biochem Pharmacol"},{"key":"2313_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00178519","volume":"88","author":"RA Lyon","year":"1986","unstructured":"Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology. 1986;88:525\u20136.","journal-title":"Psychopharmacology"},{"key":"2313_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 1988;149:159\u201363.","journal-title":"Eur J Pharmacol"},{"key":"2313_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136836","volume":"788","author":"AM Jaster","year":"2022","unstructured":"Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, et al. Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL\/6J mice. Neurosci Lett. 2022;788:136836.","journal-title":"Neurosci Lett"},{"key":"2313_CR60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00213-005-0005-8","volume":"181","author":"WE Fantegrossi","year":"2005","unstructured":"Fantegrossi WE, Kiessel CL, De la Garza R 2nd, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology. 2005;181:529\u201336.","journal-title":"Psychopharmacology"},{"key":"2313_CR61","doi-asserted-by":"crossref","unstructured":"Erkizia-Santamaria I, Martinez-Alvarez N, Salinas-Novoa L, Meana JJ, Ortega JE. Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice. Int J Neuropsychopharmacol. 2025;28:pyaf035.","DOI":"10.1093\/ijnp\/pyaf035"},{"key":"2313_CR62","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nature17629","volume":"532","author":"JA Coleman","year":"2016","unstructured":"Coleman JA, Green EM, Gouaux E. X-ray structures and mechanism of the human serotonin transporter. Nature. 2016;532:334\u20139.","journal-title":"Nature"},{"key":"2313_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev.pharmtox.42.091401.113012","volume":"42","author":"T Kenakin","year":"2002","unstructured":"Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2002;42:349\u201379.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2313_CR64","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/S0021-9258(18)53442-6","volume":"268","author":"P Samama","year":"1993","unstructured":"Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 1993;268:4625\u201336.","journal-title":"J Biol Chem"},{"key":"2313_CR65","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, et al. 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003;63:1223\u20139.","journal-title":"Mol Pharmacol"},{"key":"2313_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1073\/pnas.0708862105","volume":"105","author":"CL Schmid","year":"2008","unstructured":"Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA. 2008;105:1079\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2313_CR67","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"2313_CR68","doi-asserted-by":"crossref","unstructured":"Vohra HZ, Saunders JM, Jaster AM, de la Fuente Revenga M, Jimenez J, Fernandez-Teruel A, et al. Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6\/SvEv mice. Psychopharmacology. 2022;239:1649\u20134.","DOI":"10.1007\/s00213-021-05913-9"},{"key":"2313_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108988","volume":"209","author":"S Sierra","year":"2022","unstructured":"Sierra S, Muchhala KH, Jessup DK, Contreras KM, Shah UH, Stevens DL, et al. Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice. Neuropharmacology. 2022;209:108988.","journal-title":"Neuropharmacology"},{"key":"2313_CR70","first-page":"43","volume":"94","author":"RA Glennon","year":"1989","unstructured":"Glennon RA. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships. NIDA Res Monogr. 1989;94:43\u201367.","journal-title":"NIDA Res Monogr"},{"key":"2313_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0091-3057(93)90379-8","volume":"46","author":"RA Glennon","year":"1993","unstructured":"Glennon RA. MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM. Pharmacol Biochem Behav. 1993;46:459\u201362.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR72","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/FBP.0000000000000589","volume":"31","author":"KA Herr","year":"2020","unstructured":"Herr KA, Baker LE. Re-evaluation of the discriminative stimulus effects of lysergic acid diethylamide with male and female Sprague-Dawley rats. Behav Pharmacol. 2020;31:776\u201386.","journal-title":"Behav Pharmacol"},{"key":"2313_CR73","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"R Nardou","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569:116\u201320.","journal-title":"Nature"},{"key":"2313_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl6554","volume":"10","author":"B Rein","year":"2024","unstructured":"Rein B, Raymond K, Boustani C, Tuy S, Zhang J, St Laurent R, et al. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens. Sci Adv. 2024;10:eadl6554.","journal-title":"Sci Adv"},{"key":"2313_CR75","doi-asserted-by":"crossref","unstructured":"Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, et al. Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. Sci Transl Med. 2019;11:eaaw6435.","DOI":"10.1126\/scitranslmed.aaw6435"},{"key":"2313_CR76","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0091-3057(00)00174-X","volume":"66","author":"RA Glennon","year":"2000","unstructured":"Glennon RA, Young R. MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin. Pharmacol Biochem Behav. 2000;66:483\u20138.","journal-title":"Pharmacol Biochem Behav"},{"key":"2313_CR77","doi-asserted-by":"crossref","unstructured":"Pomrenze MB, Vaillancourt S, Salgado JS, Raymond KB, Llorach P, Touponse GC, et al. 5-HT(2C) receptors in the nucleus accumbens constrain the rewarding effects of MDMA. Mol Psychiatry. 2025;30:5405\u201316.","DOI":"10.1038\/s41380-025-03128-4"},{"key":"2313_CR78","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305\u201322.","journal-title":"J Pharmacol Exp Ther"},{"key":"2313_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177304","volume":"991","author":"JJ Gattuso","year":"2025","unstructured":"Gattuso JJ, Wilson C, Li S, Hannan AJ, Renoir T. Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin. Eur J Pharmacol. 2025;991:177304.","journal-title":"Eur J Pharmacol"},{"key":"2313_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.","journal-title":"Neuropharmacology"},{"key":"2313_CR81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00401509","volume":"11","author":"SJ Corne","year":"1967","unstructured":"Corne SJ, Pickering RW. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia. 1967;11:65\u201378.","journal-title":"Psychopharmacologia"},{"key":"2313_CR82","first-page":"249","volume":"27","author":"VV Joshi","year":"1983","unstructured":"Joshi VV, Gada VP, Balsara JJ, Chandorkar AG. Fenfluramine-induced head-twitch response in mice and its modification by certain drugs influencing the central 5-hydroxytryptamine function. Indian J Physiol Pharmacol. 1983;27:249\u201352.","journal-title":"Indian J Physiol Pharmacol"},{"key":"2313_CR83","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/BF00212780","volume":"95","author":"S Orikasa","year":"1988","unstructured":"Orikasa S, Sloley BD. Effects of 5,7-dihydroxytryptamine and 6-hydroxydopamine on head-twitch response induced by serotonin, p-chloroamphetamine, and tryptamine in mice. Psychopharmacology. 1988;95:124\u201331.","journal-title":"Psychopharmacology"},{"key":"2313_CR84","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","volume":"184","author":"C Dong","year":"2021","unstructured":"Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184:2779\u201392.e2718.","journal-title":"Cell"},{"key":"2313_CR85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-2999(86)90615-1","volume":"132","author":"MP Johnson","year":"1986","unstructured":"Johnson MP, Hoffman AJ, Nichols DE. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol. 1986;132:269\u201376.","journal-title":"Eur J Pharmacol"},{"key":"2313_CR86","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1046\/j.1460-9568.2003.02829.x","volume":"18","author":"A Bortolozzi","year":"2003","unstructured":"Bortolozzi A, Amargos-Bosch M, Adell A, Diaz-Mataix L, Serrats J, Pons S, et al. In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. Eur J Neurosci. 2003;18:1235\u201346.","journal-title":"Eur J Neurosci"},{"key":"2313_CR87","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2007","unstructured":"Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2007;189:565\u201373.","journal-title":"Psychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02313-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02313-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:13:25Z","timestamp":1777367605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02313-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02313-x","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G.-M. has a consulting agreement with\n                      Boston Interactome\n                      , and has previously received research support from\n                      Terran Biosciences\n                      and\n                      Gonogo Solutions\n                      . J.G.-M. and M.D. have also received prior research support from the\n                      Noetic Fund\n                      . M.d.l.F.R. is a full-time employee of\n                      Axsome Therapeutics\n                      , which had no role in the funding, design, conduct, or interpretation of this study. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}